European Health Data Space

LynxCare's comprehensive data asset offers fresh insights into breast cancer, including comorbidity factors, treatment patterns, and staging. With over 4800 estimated patients and 598 endpoints measured, our granular and quality-controlled real-world dataset can unlock invaluable insights into the treatment and prognosis of breast cancer patients, empowering clinicians to make informed decisions.

With over 7400 estimated patients and 610 endpoints measured, our granular and quality-controlled real-world dataset can unlock invaluable insights into the treatment and prognosis of lung cancer patients, empowering clinicians to make informed decisions.

“We are thrilled to embark on this partnership journey with Keyrus Life Science and are proud to have already set the first successful steps in France, with new geographies on our horizon,” says Georges De Feu, CEO LynxCare.

LynxCare's vast and validated datasets offers fresh insights into Multiple Myeloma (MM), including comorbidity factors, treatment patterns, and staging. With over +585 estimated patients and 348 endpoints measured, our granular and quality-controlled real world dataset can unlock invaluable insights into the treatment and prognosis of MM, empowering clinicians to make informed decisions.

LynxCare's comprehensive data asset developed from EU electronic health records offers fresh insights into Chronic Lymphocytic Leukemia, including comorbidity factors, treatment patterns, and staging. With over +800 estimated patients and 452 endpoints measured, our granular and quality controlled real-world dataset can unlock invaluable insights into the treatment and prognosis of CLL, empowering clinicians to make informed decisions.

With over 2000 estimated patients and 579 endpoints measured, our granular and quality-controlled real-world dataset can unlock invaluable insights into the treatment and prognosis of immuno-oncology (IO), empowering clinicians to make informed decisions.

We discuss the potential of the abundant RWD for lung cancer presenting an invaluable resource when translated into RWE. While clinical trials are essential, they may not fully represent the real-world patient population. RWE complements clinical trial evidence by providing insights on treatment outcomes in broader, unselected patient groups, helping inform reimbursement decisions and ensuring access to innovative therapies.

In its latest report released in June 2023, the EMA highlights key opportunities and challenges to move towards an optimized usage of RWE across the spectrum of regulatory use cases. To push this transformative vision forward, the report presents a list of lessons learned and recommendations. Continue reading below.

A study published in Clinical Pharmacology &Therapeutics [1] looking at positive marketing authorization applications of new medicines by the European Medicines Agency (EMA) in 2018-2019, found that almost all evaluated medicines included RWE signatures in the discovery (98.2%) and lifecycle management (100%) phases. About half of the medicines had RWE signatures for the full development phase (48.6%) and for supporting regulatory decisions at the registration phase (46.8%), while over a third included RWE signatures for the early development (35.1%). Therapeutic areas such as oncology, hematology, and anti-infectives showed the highest use of RWE signatures in their full development phase.